Heart Transplantation : Indications and Contraindications, Procedures and Complications.
Fleming, Catherine T.
Heart Transplantation : Indications and Contraindications, Procedures and Complications. - 1st ed. - 1 online resource (313 pages) - Cardiology Research and Clinical Developments . - Cardiology Research and Clinical Developments .
Intro -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I -- Management of Tricuspid Regurgitation After Cardiac Transplantation -- Mitesh V. Badiwala and Vivek Rao -- Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, -- Toronto General Hospital, University Health Network, Toronto, Canada -- Abstract -- Introduction -- Pathophysiology of Tricuspid Valve Regurgitation Following Cardiac Transplantation -- Management of Refractory Tricuspid Regurgitation -- Recent Experience with Repairs and Replacements -- Repair or Replacement? -- Preventing Post-Transplant TR -- Conclusion -- References -- Chapter II -- Virtual Histology Intravascular Ultrasound in Coronary Allograft Vasculopathy -- G. Sarno, W. Wijns and M. Vanderheyden -- Aalst Cardiovascular Center, Belgium. -- References -- Chapter III -- Gene Therapy for Prevention of Acute and Chronic Cardiac Rejection -- Jun-ichi Suzuki a, Mitsuaki Isobeb, -- Ryuichi Morishitac, and Ryozo Nagaid -- a Department of Advanced Clinical Science and Therapeutics, University of Tokyo, Japan -- b Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan -- cDepartment of Clinical Gene Therapy, Osaka University, Japan -- dDepartment of Cardiovascular Medicine, University of Tokyo, Japan -- Abstract -- 1. Introduction -- 2. Antisense Cyclin-Dependent Kinase (cdk) 2 Kinase ODN -- 3. Antisense Proliferating-Cell Nuclear Antigen (PCNA) ODN -- 4. Antisense Bcl-x ODN -- 5. E2F Decoy -- 6. NF-kB Decoy -- 7. Summary -- Acknowledgement -- References -- Chapter IV -- Prevention of Heart Allograft Rejection by Immunotherapy with Ex Vivo-Expanded Foxp3+CD4+CD25+ Natural Regulatory T Cells -- Guliang Xia a, Zheng Zhang a, and Bryon D. Johnson b. a Department of Surgery - Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 USA -- b Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226 USA -- Abstract -- Introduction -- Overview of Foxp3+CD4+CD25+ nTreg Cells -- Foxp3+CD4+CD25+ Treg Cells and Allograft Rejection -- Foxp3+CD4+CD25+ Treg Cells and Allograft Tolerance -- Rationale for Immunotherapy with Foxp3+CD4+CD25+ nTreg Cells -- Strategies and Procedures for Ex Vivo Expansion of CD4+CD25+ nTreg Cells -- Dynamics of Foxp3 Expression during Ex Vivo Expansion -- Suppressive Activity in MLR Assays -- Engraftment, Trafficking and Homing after Adoptive Transfer -- In Vivo Suppression and Allograft Survival -- Determinants of in Vivo Therapeutic Efficacy -- Issues Regarding CD8+CD25+ nTreg Cells -- Generation and Application of Foxp3+CD4+CD25+ iTreg Cells -- Challenges to Clinical Application -- Conclusion -- References -- Chapter V -- Addressing the Shortage of Donor Cardiac Allografts - Use of Marginal Grafts -- Silvana F. Marasco, M. Bioetha and Andrew E. Newcombb -- aCJOB Cardiothoracic Surgery Unit, The Alfred Hospital, Melbourne, Australia -- bCardiothoracic Sugery Unit, St. Vincent's Hospital, Melbourne, Australia -- Abstract -- Introduction -- Strategies to Improve Donor Organ Utilization -- Expanding the Use of Marginal Donor Organs -- Use of Marginal Cardiac Allografts for Heterotopic Transplantation -- Use of Long Ischemic Time Organs as Marginal Allografts -- Primary Graft Failure as a Consequence of Marginal Graft Use -- Older Donors and Cardiac Arrest Donors -- Continuous Perfusion of Donor Organs -- Conclusion -- References -- Chapter VI -- Dendritic Cell Modulation for Therapeutic Immunoregulation in Heart Transplantation -- Giuseppe Vassalli *a, Marc-Estienne Roehrichb, Manuel Pascualc,. Ludwig K. Von Segesserd, Pierre Vogte, -- Giovanni B. Pedrazzini f and Tiziano Moccettig -- aDepts. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, and Fondazione CardioCentro Ticino, Lugano, Switzerland -- bDept. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- cGeneva-Lausanne Transplant Network, University Hospital, Geneva and Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- dDept. of Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- eDept. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- fDept. of Cardiology, Fondazione CardioCentro Ticino, Lugano, Switzerland -- gDept. of Cardiology, Fondazione CardioCentro Ticino, Lugano, Switzerland -- Abstract -- Introduction -- Direct and Indirect Allorecognition -- Dendritic Cell Subsets and Dendritic Cell Maturation in Organ Transplantation -- Circulating Dendritic Cells in Human Organ Transplantation -- Therapeutic Strategies Based on Genetically Modified Dendritic Cells -- Therapeutic Modulation of Dendritic Cell Chemoattraction -- Generation of Regulatory Dendritics Cells -- Pharmacological Dendritic Cell Inhibitors -- Concluding Remarks -- Acknowledgements -- References -- Chapter VII -- Heart Transplantation: Indications and Contraindications, Procedures and Complications -- Katharina Kerschan-Schindl*a and Peter Pietschmannb -- a Department of Physical Medicine & -- Rehabilitation, -- Medical University of Vienna -- b Center of Physiology, Pathophysiology and Immunology, -- Medical University of Vienna -- Abstract -- Introduction -- Epidemiology -- Pathogenesis of Bone Disease in Heart Transplant Candidates and Recipients. Prevention and Treatment -- Conclusion -- Achnowledgement -- References -- Chapter VIII -- The Role of Statins in Heart Transplantation -- Nikolaos Bessias,a Panagiotis Georgakis,b -- and Kosmas I. Paraskevas*a -- a Department of Vascular Surgery, Red Cross Hospital, Athens, Greece -- b Department of Anesthesiology, Red Cross Hospital, Athens, Greece -- Abstract -- Introduction -- Transplant Coronary Artery Disease: Pathogenesis and Pathomechanisms -- Treatment of Transplant Coronary Artery Disease: The Role of Statins -- Conclusion -- References -- Chapter IX -- Heart Transplantation from Non-Heart-Beating Donors -- Future Transplantation -- Masanori Hirota* and Shunji Sano -- Departments of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan -- Abstract -- Background -- Methods -- Results -- Conclusions -- Introduction -- Donor Selection -- Who Becomes a NHBD for Heart Transplantation? -- Category 1: "Dead on Arrival" -- Category 2: "Unsuccessful Resuscitation" -- Category 3: "Awaiting Cardiac Arrest" -- Category 4: "Cardiac Arrest While Brain Dead" -- Do We Approve Pharmaceutical Pretreatments for NHB Donation? -- Resuscitation System -- History of Resuscitation System for the NHBD Hearts -- Importance of the Post-Mortem Utilization of Plasminogen Activator for Non-Pretreated Nhbds By Heparin -- Morphology of the Coronary Microvessels and How to Remove Intracoronary Microthrombi -- Reperfusion Technique -- What is the Post-Ischemic Functional Impairment Known as "Reperfusion Injury"? -- Possible Cardioprotective Determinants to Prevent Reperfusion Injury for the NHBD Hearts -- (!). Composition of Initial Perfusate (Crystalloid Cardioplegia Vs Blood Cardioplegia) -- (2). Hemotocrit Level and Temperature of Blood Cardioplegia -- (3). Ca2+ Level of Blood Cardioplegia. (4). Perfusion Pressure -- (5). Oxygen Tension of Blood Cardioplegia -- (6). Leukocyte-Depletion -- Evaluation of Post-Resuscitated (Pre-Tranaspalnt) Cardiac Function -- Preliminary Experimental Study for Clinical Application -- Material and Methods -- Surgical Preparation -- Introduction of Hypoxic Cardiac Arrest -- Isolated Myocardial Perfusion System and BCP -- Retrograde Blood Cardioplegia -- LV Function -- Statistical Analysis -- Results -- Discussion -- Conclusion -- Limitation of Our Study and Perspectives -- Second Experimental Study -- Material and Methods -- Experimental Protocol -- Introduction of Hypoxic Cardiac Arrest -- Isolated Myocardial Perfusion System and BCP -- Retrograde Blood Cardioplegia -- Lv Function -- Results -- Conclusion -- Future Clinical Trial for Heart Transplantation from NHBDs -- Acknowledgements for All Coworkers -- References -- Chapter X -- An Innovative Treatment for Cardiac Failure: Autologous Stem Cell Transplantation -- Gloria Invernici, Silvia Cristini, Stefania Navone, Laura Canzi and Eugenio A. Parati -- Laboratory of Cellular Neurobiology, U.O. Cerebrovascular Diseases, -- Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy. -- Abstract -- 1. Introduction -- 1.1 Heart Failure -- 1.2 Causes of Heart Failure -- Coronary Artery Disease and Heart Attack -- Hypertension -- Valvular Heart Disease -- Cardiomyopathy -- Myocarditis -- Congenital Heart Defects -- Abnormal Heart Rhythms (Heart Arrhythmias) -- Diabetes -- Other Diseases -- Alcohol and Drug Abuse -- 1.3 Surgical Treatment in Heart Failure -- Coronary Artery Bypass Graft Surgery (CABG) -- Repair of Mitral Valvular Regurgitation -- Left Ventricular Reconstructive Surgery or Dor Procedure -- Implantable Left Ventriclar Assist Device (LVAD) -- Heart Transplantation -- 1.4 Drug Treatment in Heart Failure -- Diuretics. Angiotensin Converting Enzyme (ACE) Inhibitors.
9781608765911
Heart -- Transplantation.
Heart -- Surgery.
Electronic books.
RD598.35.T7 -- H43 2009eb
617.4120592
Heart Transplantation : Indications and Contraindications, Procedures and Complications. - 1st ed. - 1 online resource (313 pages) - Cardiology Research and Clinical Developments . - Cardiology Research and Clinical Developments .
Intro -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I -- Management of Tricuspid Regurgitation After Cardiac Transplantation -- Mitesh V. Badiwala and Vivek Rao -- Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, -- Toronto General Hospital, University Health Network, Toronto, Canada -- Abstract -- Introduction -- Pathophysiology of Tricuspid Valve Regurgitation Following Cardiac Transplantation -- Management of Refractory Tricuspid Regurgitation -- Recent Experience with Repairs and Replacements -- Repair or Replacement? -- Preventing Post-Transplant TR -- Conclusion -- References -- Chapter II -- Virtual Histology Intravascular Ultrasound in Coronary Allograft Vasculopathy -- G. Sarno, W. Wijns and M. Vanderheyden -- Aalst Cardiovascular Center, Belgium. -- References -- Chapter III -- Gene Therapy for Prevention of Acute and Chronic Cardiac Rejection -- Jun-ichi Suzuki a, Mitsuaki Isobeb, -- Ryuichi Morishitac, and Ryozo Nagaid -- a Department of Advanced Clinical Science and Therapeutics, University of Tokyo, Japan -- b Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Japan -- cDepartment of Clinical Gene Therapy, Osaka University, Japan -- dDepartment of Cardiovascular Medicine, University of Tokyo, Japan -- Abstract -- 1. Introduction -- 2. Antisense Cyclin-Dependent Kinase (cdk) 2 Kinase ODN -- 3. Antisense Proliferating-Cell Nuclear Antigen (PCNA) ODN -- 4. Antisense Bcl-x ODN -- 5. E2F Decoy -- 6. NF-kB Decoy -- 7. Summary -- Acknowledgement -- References -- Chapter IV -- Prevention of Heart Allograft Rejection by Immunotherapy with Ex Vivo-Expanded Foxp3+CD4+CD25+ Natural Regulatory T Cells -- Guliang Xia a, Zheng Zhang a, and Bryon D. Johnson b. a Department of Surgery - Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 USA -- b Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226 USA -- Abstract -- Introduction -- Overview of Foxp3+CD4+CD25+ nTreg Cells -- Foxp3+CD4+CD25+ Treg Cells and Allograft Rejection -- Foxp3+CD4+CD25+ Treg Cells and Allograft Tolerance -- Rationale for Immunotherapy with Foxp3+CD4+CD25+ nTreg Cells -- Strategies and Procedures for Ex Vivo Expansion of CD4+CD25+ nTreg Cells -- Dynamics of Foxp3 Expression during Ex Vivo Expansion -- Suppressive Activity in MLR Assays -- Engraftment, Trafficking and Homing after Adoptive Transfer -- In Vivo Suppression and Allograft Survival -- Determinants of in Vivo Therapeutic Efficacy -- Issues Regarding CD8+CD25+ nTreg Cells -- Generation and Application of Foxp3+CD4+CD25+ iTreg Cells -- Challenges to Clinical Application -- Conclusion -- References -- Chapter V -- Addressing the Shortage of Donor Cardiac Allografts - Use of Marginal Grafts -- Silvana F. Marasco, M. Bioetha and Andrew E. Newcombb -- aCJOB Cardiothoracic Surgery Unit, The Alfred Hospital, Melbourne, Australia -- bCardiothoracic Sugery Unit, St. Vincent's Hospital, Melbourne, Australia -- Abstract -- Introduction -- Strategies to Improve Donor Organ Utilization -- Expanding the Use of Marginal Donor Organs -- Use of Marginal Cardiac Allografts for Heterotopic Transplantation -- Use of Long Ischemic Time Organs as Marginal Allografts -- Primary Graft Failure as a Consequence of Marginal Graft Use -- Older Donors and Cardiac Arrest Donors -- Continuous Perfusion of Donor Organs -- Conclusion -- References -- Chapter VI -- Dendritic Cell Modulation for Therapeutic Immunoregulation in Heart Transplantation -- Giuseppe Vassalli *a, Marc-Estienne Roehrichb, Manuel Pascualc,. Ludwig K. Von Segesserd, Pierre Vogte, -- Giovanni B. Pedrazzini f and Tiziano Moccettig -- aDepts. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, and Fondazione CardioCentro Ticino, Lugano, Switzerland -- bDept. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- cGeneva-Lausanne Transplant Network, University Hospital, Geneva and Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- dDept. of Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- eDept. of Cardiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland -- fDept. of Cardiology, Fondazione CardioCentro Ticino, Lugano, Switzerland -- gDept. of Cardiology, Fondazione CardioCentro Ticino, Lugano, Switzerland -- Abstract -- Introduction -- Direct and Indirect Allorecognition -- Dendritic Cell Subsets and Dendritic Cell Maturation in Organ Transplantation -- Circulating Dendritic Cells in Human Organ Transplantation -- Therapeutic Strategies Based on Genetically Modified Dendritic Cells -- Therapeutic Modulation of Dendritic Cell Chemoattraction -- Generation of Regulatory Dendritics Cells -- Pharmacological Dendritic Cell Inhibitors -- Concluding Remarks -- Acknowledgements -- References -- Chapter VII -- Heart Transplantation: Indications and Contraindications, Procedures and Complications -- Katharina Kerschan-Schindl*a and Peter Pietschmannb -- a Department of Physical Medicine & -- Rehabilitation, -- Medical University of Vienna -- b Center of Physiology, Pathophysiology and Immunology, -- Medical University of Vienna -- Abstract -- Introduction -- Epidemiology -- Pathogenesis of Bone Disease in Heart Transplant Candidates and Recipients. Prevention and Treatment -- Conclusion -- Achnowledgement -- References -- Chapter VIII -- The Role of Statins in Heart Transplantation -- Nikolaos Bessias,a Panagiotis Georgakis,b -- and Kosmas I. Paraskevas*a -- a Department of Vascular Surgery, Red Cross Hospital, Athens, Greece -- b Department of Anesthesiology, Red Cross Hospital, Athens, Greece -- Abstract -- Introduction -- Transplant Coronary Artery Disease: Pathogenesis and Pathomechanisms -- Treatment of Transplant Coronary Artery Disease: The Role of Statins -- Conclusion -- References -- Chapter IX -- Heart Transplantation from Non-Heart-Beating Donors -- Future Transplantation -- Masanori Hirota* and Shunji Sano -- Departments of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan -- Abstract -- Background -- Methods -- Results -- Conclusions -- Introduction -- Donor Selection -- Who Becomes a NHBD for Heart Transplantation? -- Category 1: "Dead on Arrival" -- Category 2: "Unsuccessful Resuscitation" -- Category 3: "Awaiting Cardiac Arrest" -- Category 4: "Cardiac Arrest While Brain Dead" -- Do We Approve Pharmaceutical Pretreatments for NHB Donation? -- Resuscitation System -- History of Resuscitation System for the NHBD Hearts -- Importance of the Post-Mortem Utilization of Plasminogen Activator for Non-Pretreated Nhbds By Heparin -- Morphology of the Coronary Microvessels and How to Remove Intracoronary Microthrombi -- Reperfusion Technique -- What is the Post-Ischemic Functional Impairment Known as "Reperfusion Injury"? -- Possible Cardioprotective Determinants to Prevent Reperfusion Injury for the NHBD Hearts -- (!). Composition of Initial Perfusate (Crystalloid Cardioplegia Vs Blood Cardioplegia) -- (2). Hemotocrit Level and Temperature of Blood Cardioplegia -- (3). Ca2+ Level of Blood Cardioplegia. (4). Perfusion Pressure -- (5). Oxygen Tension of Blood Cardioplegia -- (6). Leukocyte-Depletion -- Evaluation of Post-Resuscitated (Pre-Tranaspalnt) Cardiac Function -- Preliminary Experimental Study for Clinical Application -- Material and Methods -- Surgical Preparation -- Introduction of Hypoxic Cardiac Arrest -- Isolated Myocardial Perfusion System and BCP -- Retrograde Blood Cardioplegia -- LV Function -- Statistical Analysis -- Results -- Discussion -- Conclusion -- Limitation of Our Study and Perspectives -- Second Experimental Study -- Material and Methods -- Experimental Protocol -- Introduction of Hypoxic Cardiac Arrest -- Isolated Myocardial Perfusion System and BCP -- Retrograde Blood Cardioplegia -- Lv Function -- Results -- Conclusion -- Future Clinical Trial for Heart Transplantation from NHBDs -- Acknowledgements for All Coworkers -- References -- Chapter X -- An Innovative Treatment for Cardiac Failure: Autologous Stem Cell Transplantation -- Gloria Invernici, Silvia Cristini, Stefania Navone, Laura Canzi and Eugenio A. Parati -- Laboratory of Cellular Neurobiology, U.O. Cerebrovascular Diseases, -- Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy. -- Abstract -- 1. Introduction -- 1.1 Heart Failure -- 1.2 Causes of Heart Failure -- Coronary Artery Disease and Heart Attack -- Hypertension -- Valvular Heart Disease -- Cardiomyopathy -- Myocarditis -- Congenital Heart Defects -- Abnormal Heart Rhythms (Heart Arrhythmias) -- Diabetes -- Other Diseases -- Alcohol and Drug Abuse -- 1.3 Surgical Treatment in Heart Failure -- Coronary Artery Bypass Graft Surgery (CABG) -- Repair of Mitral Valvular Regurgitation -- Left Ventricular Reconstructive Surgery or Dor Procedure -- Implantable Left Ventriclar Assist Device (LVAD) -- Heart Transplantation -- 1.4 Drug Treatment in Heart Failure -- Diuretics. Angiotensin Converting Enzyme (ACE) Inhibitors.
9781608765911
Heart -- Transplantation.
Heart -- Surgery.
Electronic books.
RD598.35.T7 -- H43 2009eb
617.4120592